HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- (3- (3- (bis(4- isobutylphenyl)methylamino)benzoyl)- 1H- indol- 1- yl)butyric acid

structure given in first source

Also Known As:

FK 143; FK-143; FK143

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 4-(3-(3-(bis(4-isobutylphenyl)methylamino)benzoyl)-1H-indol-1-yl)butyric acid: 3
Organic Chemicals: 133
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Phenylbutyrates
      - 4-(3-(3-(bis(4-isobutylphenyl)methylamino)benzoyl)-1H-indol-1-yl)butyric acid: 3

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 06/04/1997 - "This study was conducted to determine if a 5alpha-reductase inhibitor, FK143, inhibits the development of prostate cancer in rats. " 06/04/1997 - "The 5alpha-reductase inhibitor FK143 may, at specific doses, reduce the incidence of spontaneously developing prostate cancer; however, whether these findings in rats will apply to humans remains to be determined." 06/04/1997 - "Male ACI/Seg rats, which spontaneously develop prostate cancer, were randomly assigned at 80 weeks of age to receive one of three diets (n = 35/group) containing 0 (i.e., control group), 20, or 200 ppm FK143. "
2.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 04/01/1999 - "FK143 also has in vivo inhibitory activity against the castrated young rat model and it should therefore be an extremely useful agent for the treatment of benign prostatic hyperplasia." 06/01/1997 - "These results demonstrate that FK143 can decrease the volume of the dog prostate without any influence on other organs, and they suggest that FK143 is a good candidate for the treatment for benign prostatic hyperplasia."
3.	Carcinogenesis 06/04/1997 - "Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143."
4.	Atrophy 06/01/1997 - "At doses of 10 and 32 mg/kg, FK143 significantly reduced prostate volume to about 60% of the initial value, and dogs treated with FK143 showed a dose-dependent glandular epithelial atrophy in the prostate. "